In fiscal year 2025, TiumBio (321550) reported revenue of 12.3 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 12.3 billion KRW | -16.1 billion KRW | -18.8 billion KRW | [source] |
| 2024 | 6.8 billion KRW | -18.7 billion KRW | -23.5 billion KRW | [source] |
| 2023 | 4.9 billion KRW | -27.8 billion KRW | -19.0 billion KRW | [source] |
| 2022 | — | -25.6 billion KRW | -31.4 billion KRW | [source] |
| 2021 | — | -32.7 billion KRW | -32.3 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 83.7 billion KRW | 39.1 billion KRW | 44.6 billion KRW | [source] |
| 2024 | 91.5 billion KRW | 38.0 billion KRW | 53.5 billion KRW | [source] |
| 2023 | 103.6 billion KRW | 33.9 billion KRW | 69.7 billion KRW | [source] |
| 2022 | 92.1 billion KRW | 31.2 billion KRW | 60.9 billion KRW | [source] |
| 2021 | 108.1 billion KRW | 20.2 billion KRW | 87.9 billion KRW | [source] |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.